Georg, Unless the data changed from when David Barlow Presented it in the UK, the indications were that combining imipramine with CBT produced a long term disadvantage, not merely no advantage. This echoes work with CBT/alprazolam. Perhaps the most interesting result from his presentation at the British Association for Behavioural and Cognitive Psychotherapy conference was that the data indicate that the any effects of adding imipramine to CBT may be accounted for by placebo effects, and that the administration of a placebo medication disadvantaged (after discontinuation) those given cbt in a similar way to those given imipramine. Very very interesting, should lead us to re-evaluate the significance of other cbt/drug combination studies.